Ocugen, Inc. OCGN
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026
Ocugen, Inc. (OCGN) is a healthcare company listed in the US with a market value of about $281M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$65M, a net margin of -1367.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 152% a year, a 5-year average ROIC of -132%.
About Ocugen
Ocugen is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $43000 in 2020 to $4M in 2025, growth of about 152.5% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 58% over three years (dilution for shareholders). It spends 901% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5M | $4M | $4M | $6M | $2M | $0 | $43000 |
| Net income | -$65M | -$68M | -$54M | -$63M | -$87M | -$58M | -$22M |
| Free cash flow | -$64M | -$57M | -$46M | -$73M | -$65M | -$49M | -$15M |
| EPS (diluted) | $-0.20 | $-0.20 | — | $-0.26 | $-0.40 | $-0.30 | $-0.31 |
| Net margin | -1367.6% | -1537.4% | -1333.0% | -1045.0% | -3488.9% | — | -50748.8% |
| ROIC | — | -265.6% | -83.0% | -137.9% | -110.9% | -61.4% | -88.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $12.17, 1370% above the current price; targets range from $8.00 to $22.00; the consensus rating is “Strong buy”; expected EPS is $-0.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Ocugen pay a dividend?
Not currently.
Is Ocugen a good stock to buy?
We do not give buy or sell advice. Ocugen scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.